Semaglutide

Overview

Semaglutide is the most widely prescribed and longest-studied GLP-1 receptor agonist for weight management — the molecule that effectively transformed obesity medicine into a chronic-disease pharmacotherapy field. First approved by the FDA for type 2 diabetes in 2017, then for chronic weight management in June 2021, semaglutide established what has come to be known as the “GLP-1 era”: a fundamental shift in what’s clinically achievable for adults with obesity using a once-weekly injection.

In 2026, semaglutide remains the default starting point for many Tennessee patients exploring medical weight management. It has the broadest payer coverage among GLP-1-class therapies, the strongest cardiovascular outcomes evidence to date, and a real-world safety record spanning nearly a decade of broad clinical use. It now sits alongside tirzepatide (a higher-efficacy dual agonist approved in 2022 and 2023) and the investigational retatrutide (a triple agonist that read out striking phase 3 data in late 2025) in a rapidly evolving therapeutic class.

For most Tennessee patients, the choice between semaglutide and the newer molecules involves more than peak weight-loss magnitude: insurance coverage, comorbidities, tolerability, and the depth of real-world clinical experience all matter. This page covers what semaglutide does, the trial evidence behind it, the 2026 regulatory landscape, and how it compares to the rest of the GLP-1 class.

How Semaglutide Works

Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1), a gut hormone released after meals. Native GLP-1 has a half-life of only a few minutes — it’s degraded by an enzyme called DPP-4 almost as quickly as it’s released. Semaglutide is engineered to resist that degradation, achieving a half-life of approximately one week. This is what enables once-weekly subcutaneous dosing.

At the GLP-1 receptor, semaglutide activates the same signaling pathways as the natural hormone but for a far longer duration. The clinically meaningful effects fall into three domains.

Central nervous system — appetite regulation. GLP-1 receptors are expressed throughout the hypothalamus and brainstem, in circuits that govern hunger, satiety, and food reward. Semaglutide activates these circuits, reducing hunger, prolonging fullness after meals, and dampening the “interest” in food that drives between-meal eating. Most patients describe this as the dominant subjective experience of therapy.

Gastrointestinal — slowed gastric emptying. Semaglutide slows the rate at which food moves out of the stomach. This prolongs postprandial fullness and contributes meaningfully to reduced caloric intake. It is also the primary mechanism behind nausea and other GI side effects at therapeutic doses.

Pancreatic — glucose-dependent insulin secretion. Semaglutide stimulates pancreatic insulin release when blood glucose is elevated and simultaneously suppresses glucagon. This produces durable HbA1c and fasting glucose improvements in type 2 diabetes without producing hypoglycemia in patients with normal glucose regulation.

For patients, the clinical experience tends to follow a predictable arc: appetite changes appear within the first two weeks, measurable weight loss begins by week four, and steady weekly loss continues through dose escalation and into the early maintenance phase.

Clinical Evidence: The STEP Program

Semaglutide’s role in chronic weight management is grounded in the STEP (Semaglutide Treatment Effect in People with Obesity) program — a series of large, randomized, placebo-controlled phase 3 trials that established its efficacy and supported FDA approval. The follow-on SELECT trial extended the evidence to cardiovascular outcomes.

STEP-1 (Wilding et al., NEJM 2021 [1]) was the pivotal weight-loss trial. 1,961 adults with obesity or overweight without type 2 diabetes were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. The semaglutide arm achieved a mean body weight reduction of 14.9% versus 2.4% on placebo. 86.4% of treated patients achieved at least 5% weight loss; 69.1% achieved at least 10%; and 50.5% achieved at least 15% — clinical thresholds that had previously been associated almost exclusively with bariatric surgery.

STEP-3 combined semaglutide with intensive behavioral therapy and produced a 16.0% mean weight loss — modestly greater than STEP-1, and useful evidence that pharmacotherapy and behavioral intervention stack rather than substitute.

STEP-4 (Rubino et al., JAMA 2021 [3]) addressed the durability question. After a 20-week run-in on semaglutide, patients were re-randomized to continue therapy or switch to placebo. The continuation arm lost an additional 7.9% of body weight over the following 48 weeks; the placebo-switched arm regained 6.9%. This trial is the foundation for the clinical framing of semaglutide as long-term maintenance therapy rather than a short-term intervention.

STEP-5 (Garvey et al., Nat Med 2022 [2]) extended the duration to 104 weeks. Mean weight change was −15.2% with semaglutide versus −2.6% with placebo, with 77.1% of treated patients achieving at least 5% weight loss at week 104. The trial confirmed that weight loss achieved during the first year of therapy is largely sustained at year two when therapy is continued.

STEP-HFpEF evaluated semaglutide in adults with heart failure with preserved ejection fraction and an obesity phenotype. The trial reported significant improvements in heart failure symptom scores, physical function, and exercise capacity, opening a use case beyond weight reduction alone.

STEP-TEENS (Weghuber et al., NEJM 2022 [5]) evaluated semaglutide in adolescents with obesity, reporting a placebo-subtracted body weight change of −17.4 percentage points — a magnitude of effect that has reshaped pediatric obesity management discussions.

SELECT (Lincoff et al., NEJM 2023 [4]) was the cardiovascular outcomes trial. In adults with established cardiovascular disease and obesity but without diabetes, semaglutide produced a 20% reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). SELECT was the basis for the 2024 FDA expansion approving semaglutide for cardiovascular risk reduction in patients with obesity or overweight and established CVD — a label expansion that has since reshaped payer coverage.

Benefits Beyond Weight Loss

The most clinically significant extension of semaglutide’s value beyond weight loss is the SELECT trial’s cardiovascular outcomes data. A 20% reduction in MACE in patients with established cardiovascular disease, achieved through a once-weekly subcutaneous injection, is on par with the most effective cardioprotective therapies ever studied — and it’s achieved primarily through a weight-loss and metabolic-health pathway. For Tennessee patients with obesity and established cardiovascular disease, semaglutide is now framed not just as a weight-loss medication but as a cardiovascular risk-reduction therapy. This is currently the only GLP-1-class molecule with FDA-approved labeling for that indication.

STEP-HFpEF’s heart failure findings open a parallel use case. Patients with HFpEF and obesity who received semaglutide showed meaningful improvements in symptom severity, physical functioning, and exercise capacity. Given that HFpEF is one of the fastest-growing heart-failure phenotypes nationally and is notoriously difficult to treat, this is a substantive addition to the available toolkit.

Beyond the trial-confirmed outcomes, semaglutide consistently produces reductions in blood pressure (typically 4–6 mmHg systolic), favorable changes in lipid panels (modest LDL reduction, more substantial triglyceride reduction, modest HDL increase), reductions in CRP and other inflammatory markers, and meaningful HbA1c reductions in patients with type 2 diabetes. For patients with multiple cardiometabolic comorbidities, the cumulative value of these effects often outweighs the weight-loss endpoint in isolation.

Semaglutide Dosing Protocol

Semaglutide for weight management is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. The standard titration schedule used in the STEP program and recommended in current labeling is:

• Weeks 1–4: 0.25 mg weekly (starting dose; subtherapeutic, intended for tolerability)
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (target maintenance dose)

The 16-week titration is structured around tolerability rather than efficacy. Gastrointestinal symptoms — primarily nausea — are dose-dependent and tend to peak with each step up. The four-week dwell time at each step gives patients an opportunity to adapt before escalation. Patients who experience significant GI symptoms can remain at the current dose for an additional cycle before attempting the next step, or settle at a maintenance dose below 2.4 mg if symptoms persist or weight loss is satisfactory.

An oral semaglutide formulation received expanded FDA approval for chronic weight management in 2026 (the oral tablet had been approved for type 2 diabetes since 2019). The oral 50 mg daily formulation produces approximately 15% body weight loss in trials — comparable in magnitude to the 2.4 mg weekly injection. Oral semaglutide is taken in the morning on an empty stomach with no more than 4 oz of water and no food, drink, or other oral medications for at least 30 minutes after dosing. The injection-versus-oral choice in Tennessee clinics is increasingly individualized around patient preference and adherence patterns rather than efficacy.

Side Effects and Tolerability

Across the STEP trials, semaglutide’s side effect profile is dominated by gastrointestinal symptoms. Reported frequencies in STEP-1: nausea approximately 44%, diarrhea approximately 32%, vomiting approximately 24%, constipation approximately 24%, abdominal pain, decreased appetite, dyspepsia, eructation (belching), and fatigue. The majority of GI events were mild to moderate, occurred most frequently during dose escalation, and attenuated with continued exposure at the same dose.

Discontinuation rates due to adverse events across STEP trials were typically 4–7%, a low rate considering the magnitude of physiologic effect. Severe pancreatitis is a rare but recognized risk; patients with a history of pancreatitis are managed with caution or excluded. Gallbladder events (cholelithiasis, cholecystitis) occur at modestly elevated rates in patients losing substantial weight on any GLP-1-class medication. Injection-site reactions are uncommon and typically mild.

Hypoglycemia is rare in non-diabetic patients but can occur in patients on concurrent insulin or sulfonylureas; these medications often require dose adjustment at semaglutide initiation. Diabetic retinopathy in patients with poorly controlled type 2 diabetes may transiently worsen as glycemia improves rapidly, warranting baseline ophthalmologic evaluation in at-risk patients.

For Tennessee patients, practical side-effect management mirrors that of the broader GLP-1 class: smaller meals, simpler foods on the days following an injection, avoidance of high-fat and ultra-processed foods, generous hydration, and continued dialogue with the prescribing clinic during titration.

Contraindications

Semaglutide is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any of its excipients

The thyroid contraindication derives from rodent C-cell tumor data with chronic GLP-1 receptor agonism. The human clinical relevance remains uncertain, but the FDA’s boxed warning is class-wide.

Caution is indicated in patients with:

• A history of pancreatitis (use with additional monitoring)
• Severe gastrointestinal disease, including gastroparesis
• Active proliferative diabetic retinopathy
• Active gallbladder disease
• Pregnancy or planned pregnancy (effective contraception is recommended; the medication should be discontinued at least 2 months before a planned pregnancy)

For surgical patients, current society guidance recommends pausing semaglutide and other GLP-1-class medications before procedures requiring general anesthesia due to the risk of retained gastric contents. Tennessee clinics coordinate timing with surgical teams as needed.

Legal and Regulatory Status in 2026

Semaglutide’s regulatory landscape has evolved substantially since initial approval and continues to shift. As of May 2026, the picture for Tennessee patients is as follows.

Brand-name semaglutide is fully FDA-approved and widely available through retail pharmacies in TN. Current approved indications span type 2 diabetes (subcutaneous, since 2017), chronic weight management (subcutaneous 2.4 mg, since June 2021), oral type 2 diabetes (since 2019), oral chronic weight management (2026), and cardiovascular risk reduction in adults with obesity or overweight and established CVD (since 2024). For type 2 diabetes and cardiovascular risk reduction, the medication is commonly covered by commercial insurance, TennCare, and Medicare Part D. Coverage for chronic weight management is more variable — most commercial plans and TennCare have historically excluded obesity medications, though employer-sponsored coverage is gradually expanding and the SELECT data has driven some plans to begin covering it for cardiovascular indications. Cash pricing for brand-name product is approximately $900–1,300 per month depending on dose and pharmacy.

The compounded semaglutide landscape has changed dramatically. The FDA officially resolved the semaglutide shortage in February 2025, ending the regulatory basis for broad outsourcing-facility (503B) compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. Wind-down enforcement deadlines completed in May 2025. Compounding under section 503A — state-licensed pharmacies producing patient-specific medications under a valid prescription — continues to operate, but the FDA has tightened enforcement and clarified that 503A compounding cannot be a substitute for the approved drug in routine practice. Patient-specific medical necessity must be documented in the chart.

On April 30, 2026, the FDA announced a proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list [6], finding “no clinical need” for bulk compounding of these molecules now that approved products are commercially available. The public comment period closes June 29, 2026, with a final rule expected later in 2026. If finalized, this would end 503B outsourcing-facility production of semaglutide entirely.

What this means practically for Tennessee patients:

• Brand-name semaglutide is fully available and is the safest legal option. The two limiting factors are cost and, for weight-management indications, insurance coverage.
• 503A patient-specific compounded semaglutide continues to exist for narrow patient-specific medical necessity, but availability is contracting. Historical pricing was $150–300 per month when broadly available; current pricing and access vary considerably and the regulatory environment is in flux.
• “Research peptide” channels that market semaglutide outside the regulated drug system are not legitimate therapeutic options. Products labeled “research use only” are not regulated as drugs, are not intended for human use, and exist outside the legal framework that governs prescribed medications.

Tennessee patients should verify that any compounded semaglutide is sourced through a licensed prescribing clinician working with a 503A pharmacy that maintains current state licensure. Reputable clinics are transparent about their pharmacy partners and about whether the product dispensed is brand-name or compounded.

Semaglutide vs Tirzepatide vs Retatrutide

The three molecules most commonly compared in 2026 weight-management discussions are semaglutide, tirzepatide, and retatrutide. They span a clean mechanistic progression from single GLP-1 agonism to dual GIP/GLP-1 agonism to triple GIP/GLP-1/glucagon agonism, with weight-loss magnitudes that track that progression.

The trade-offs go beyond peak efficacy. Semaglutide has the longest real-world track record of the three, the only completed cardiovascular outcomes trial with a positive MACE-reduction signal (SELECT), and the broadest payer coverage, particularly post-SELECT for cardiovascular indications. For patients with cardiovascular disease as a primary clinical concern, semaglutide is currently the only GLP-1-class molecule with FDA-approved labeling for that indication.

Tirzepatide produces more weight loss in head-to-head data, and its evidence base is rapidly expanding (sleep apnea, MASH, heart failure with preserved ejection fraction). Patients prioritizing maximum weight-loss magnitude and accepting somewhat newer real-world experience often start with tirzepatide.

Retatrutide is investigational. It is not FDA-approved for any indication and cannot be legally prescribed outside enrolled clinical trials. For most Tennessee patients planning therapy in 2026, retatrutide is a watch-this-space item rather than a current option.

For many TN patients, the right starting point in 2026 is semaglutide — particularly where cardiovascular disease, insurance coverage, or depth of real-world tolerability evidence are central concerns. Patients who plateau on semaglutide or want maximum weight-loss efficacy can subsequently transition to tirzepatide.

Finding a Semaglutide Provider in Tennessee

Semaglutide is offered by a broad and growing population of clinics across Tennessee. In Nashville and the Middle TN corridor (Franklin, Brentwood, Murfreesboro, Hendersonville, Clarksville), semaglutide is widely available through weight-management practices, concierge primary care, endocrinology groups, cardiometabolic specialty clinics, and dedicated peptide providers. Knoxville and East TN markets (Chattanooga, Johnson City, Kingsport, Oak Ridge) have built semaglutide into their formularies. Memphis and West Tennessee have several established weight-management practices offering it.

Smaller TN cities generally have at least one semaglutide-prescribing clinic within a reasonable drive, and telehealth-bridged prescribing has further reduced geographic barriers across the state.

When selecting a Tennessee provider, key questions to ask:

• Is the clinic prescribing brand-name semaglutide, 503A patient-specific compounded semaglutide, or both? What pharmacy partner do they work with?
• How is dosing structured? Standard 16-week titration aligned with the STEP protocol, or modified?
• What is the cadence of follow-up appointments and lab work?
• What is included in the monthly cost — medication only, or also visits, labs, and clinical support?
• Is there an oral semaglutide option for patients who prefer to avoid injections?
• What is the plan for long-term maintenance or dose tapering if appropriate?

Clinics that answer these questions clearly and transparently are generally a good signal of patient-focused practice.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414-1425.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.
5. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022.
6. U.S. Food and Drug Administration. Proposed Rule: Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List. April 30, 2026.